FDA clearance of the first Alzheimer's blood test marks a significant step toward earlier, more straightforward diagnosis—potentially improving care for adults with memory concerns.
The work of the Centers for Disease Control and Prevention, within the U.S. Department of Health & Human Services is examined here, with a special focus on traumatic brain injury.
Michael Roth, Research Group Leader at University Hospital Basel asks if fine dust air pollution (PM2.5) is a cause of chronic inflammatory lung diseases and provides a most engaging response.
More can be done at the local, national and EU level to improve COPD diagnosis, support smoking cessation and advance work and living conditions for people living with COPD.
Dr Tejas Patel, a world-renowned interventional cardiologist and endovascular therapist, highlights cardiovascular disease, a leading cause of disability and premature death around the world.
Here we find out how The Japanese Society of Nephrology engages in research developing human resources, providing lifelong education and disseminating knowledge to the public, to tackle kidney disease and promote health.
Steve Jones, Chair Action for Pulmonary Fibrosis and Board Member EU-IPFF and Gisli Jenkins from Nottingham University Hospitals, explain idiopathic pulmonary fibrosis (IPF), an incurable lung disease.
Contributing scientists share their thoughts around the field of chemistry, focussing on enzyme activity assays for disease diagnosis, novel drug development validation and nanoparticles.
Thomas Münzel MD, Andreas Daiber PhD, Ulrich Pöschl PhD and Jos Lelieveld PhD discuss the link between air pollution and cardiovascular disease in Europe.
Cardiovascular diseases are on the rise, but so is confusion as to how to prevent them. Shaun Ingram, MD of Cardiac Science takes a look at the data, shares his views and strikes a cautious note of optimism.
John Greenwood PhD FRCPath and Stephen E. Moss PhD from UCL Institute of Ophthalmology discuss the vasculature in health and disease, a major focus of their research.
Here, Open Access Government explore how the National Eye Institute in the U.S is supporting vision research that encompasses visual impairment diseases of people of all ages.
Makoto Suematsu, President of the Japan Agency for Medical Research and Development (AMED) details the challenges around global data sharing for orphan diseases.
